B-cell chronic lymphocytic leukemia (B-CLL) represents a human neoplastic disorder which arises primarily because of failures in the normal mechanisms for the cell turnover through programmed cell death, rather than as a result of alterations in cell cycle regulation. Genetic alterations that inhibit normal programmed cell death can render tumor cells more resistant to apoptosis induction by anticancer drugs. Previous studies have documented abnormalities in the expression of certain Bcl-2 family proteins in B-CLLs. This family of proteins plays a critical role in controlling cellular responses to apoptotic stimuli, including those induced by essentially all chemotherapeutic drugs. The central hypothesis to be tested in this proposal is that alterations in the expression or function of apoptosis-regulatory proteins represents a critical obstacle to successfully treating B-CLL. Among the questions that will be addressed during the testing of this hypothesis are : (1) Can differences in the expression or phosphorylation states of Bcl-2-, IAP-, caspase-family proteins explain why some B-CLL patients exhibit complete responses (CR) to chemotherapy while other do not (NR; PR)?; (2) How do purine nucleosides used in the treatment of B-CLL affect the expression or function of these apoptosis-regualtory proteins, and do differences in these events account for variations in clinical responses? Moreover is there a functional connection between purine nucleosides and the pro-apoptotic, dATP-binding protein Apaf-1? (3) Can kinase modulatory drugs, cytokines, or retinoids be employed in vitro for modulating the expression or function of apoptosis regulatory proteins, thus rendering B-CLLs more sensitive to conventional chemotherapeutic drugs? The results of these investigations are anticipated to improve understanding of the relation between defective apoptosis mechanisms in B-CLL and responses to therapy, and thus may generate strategies for improving the treatment of B- CLL patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA081534-01
Application #
6259045
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-05-01
Project End
2000-04-30
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Veronese, A; Pepe, F; Chiacchia, J et al. (2015) Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. Leukemia 29:86-95
Maji, Santanu; Samal, Sabindra K; Pattanaik, Laxmipriya et al. (2015) Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget 6:16623-37
Wu, Bainan; Wang, Si; De, Surya K et al. (2015) Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol 22:876-87
Lamothe, Betty; Cervantes-Gomez, Fabiola; Sivina, Mariela et al. (2015) Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 125:407-10
Wu, Bainan; Barile, Elisa; De, Surya K et al. (2015) High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. Curr Top Med Chem 15:2032-42
Laganà, Alessandro; Acunzo, Mario; Romano, Giulia et al. (2014) miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res 42:5416-25
Smith, Erin N; Jepsen, Kristen; Khosroheidari, Mahdieh et al. (2014) Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments. Genome Biol 15:420
McClanahan, Fabienne; Gribben, John (2014) Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies? Hematol Oncol Clin North Am 28:1055-71
Vamos, Mitchell; Welsh, Kate; Finlay, Darren et al. (2013) Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS Chem Biol 8:725-32
Hudson, Robert S; Yi, Ming; Volfovsky, Natalia et al. (2013) Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Mol Cancer 12:13

Showing the most recent 10 out of 36 publications